You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lipid lowering therapies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Coronary Syndrome, Myocardial Infarction, Ischemic Stroke Trial in Dudley (Decision Support System (DSS))

Recruiting
  • Acute Coronary Syndrome
  • +2 more
  • Decision Support System (DSS)
  • Dudley, West Midlands, United Kingdom
    Russell's Hall Hospital
Apr 25, 2023

Hypercholesterolemia, Hypercholesterolemia, Familial Trial in Cambridge (PCSK9 inhibitor, 68Ga-DOTATATE PET-MRI)

Not yet recruiting
  • Hypercholesterolemia
  • +3 more
  • Cambridge, United Kingdom
    University of Cambridge
Jan 13, 2023

Statin, Risk Factors, Primary Prevention Trial in Nanjing (Coronary Computed Tomography Angiography, No Intervention)

Not yet recruiting
  • Statin
  • +2 more
  • Coronary Computed Tomography Angiography
  • No Intervention
  • Nanjing, Jiangsu, China
    Research Institute Of Medical Imaging Jinling Hospital
Feb 15, 2023

Telenursing Lipid Lowering Medication Adherence Trial (SMS reminder massages about adherence)

Not yet recruiting
  • Telenursing Lipid Lowering Medication Adherence
  • SMS reminder massages about adherence
  • (no location specified)
May 15, 2023

Coronary Artery Disease Progression Trial in Amsterdam

Recruiting
  • Coronary Artery Disease Progression
    • Amsterdam, Noord-Holland, Netherlands
      Amsterdam UMC, location AMC
    Mar 23, 2023

    Coronary Artery Disease Trial in Aarhus (atorvastatin, rosuvastatin, ezetimibe)

    Completed
    • Coronary Artery Disease
    • High intensity lipid lowering
    • Aarhus, Denamrk, Denmark
      Aarhus University Hospital
    Nov 9, 2022

    Inclisiran Plus Standard of Care Lipid-lowering Therapy Compared

    Recruiting
    • Primary Hypercholesterolemia
    • Mixed Dyslipidemia
    • Inclisiran
    • Geneve 14, Switzerland
      Novartis Investigative Site
    Nov 14, 2022

    Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis Trial in Worldwide (Early Intervention)

    Recruiting
    • Cardiovascular Diseases
    • +3 more
    • Early Intervention
    • Wollongong, New South Wales, Australia
    • +15 more
    Nov 6, 2022

    Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia Trial (combination product, drug, other)

    Not yet recruiting
    • Dyslipidemias
    • +4 more
    • Combination Therapy
    • +5 more
    • (no location specified)
    Aug 22, 2023

    Adverse Effect of Cardiovascular Medications (Diagnosis) Trial in Zibo (Evolocumab combined with statins, Statin)

    Recruiting
    • Adverse Effect of Cardiovascular Medications (Diagnosis)
    • Evolocumab combined with statins
    • Statin
    • Zibo, Shandong, China
      Zibo Central Hospital
    Mar 24, 2023

    Treatment Side Effects Trial in Sao Paulo (Lipid-lowering agents (Artovastatin))

    Terminated
    • Treatment Side Effects
    • Lipid-lowering agents (Artovastatin)
    • Sao Paulo, Brazil
      Samuel Katsuyuki Shinjo
    May 31, 2022

    Hyperlipidemias Trial in Belfast (Fenugreek Seed Tea, Black Tea)

    Recruiting
    • Hyperlipidemias
    • Fenugreek Seed Tea
    • Black Tea
    • Belfast, Northern Ireland, United Kingdom
    • +1 more
    May 5, 2023

    Dyslipidemias, Atherosclerotic Cardiovascular Disease Trial in Amman

    Not yet recruiting
    • Dyslipidemias
    • Atherosclerotic Cardiovascular Disease
      • Amman, Jordan
      • +1 more
      Nov 23, 2022

      Coronary Artery Disease Progression Trial (Intensive lipid-lowering control, Moderate-intensity lipid-lowering control)

      Not yet recruiting
      • Coronary Artery Disease Progression
      • Intensive lipid-lowering control
      • Moderate-intensity lipid-lowering control
      • (no location specified)
      Jul 13, 2022

      Hypercholesterolemia Trial (Inclisiran, Ezetimibe, Matching Placebo for Inclisiran)

      Not yet recruiting
      • Hypercholesterolemia
      • (no location specified)
      Feb 28, 2023

      LDL-cholesterol Trial in Jena (statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran)

      Recruiting
      • LDL-cholesterol
      • statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
      • Jena, Thuringia, Germany
        University Hospital Jena
      Oct 17, 2022

      Dyslipidemias Trial in Samara (Combined Lipid-lowering Therapy)

      Recruiting
      • Dyslipidemias
      • Combined Lipid-lowering Therapy
      • Samara, Russian Federation
        Samara Regional Cardiology Dispansery
      Nov 17, 2022

      Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia Trial in Yongin (Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg)

      Recruiting
      • Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
      • Evolocumab 140 MG/ML
      • +2 more
      • Yongin, Gyeonggi-do, Korea, Republic of
        Yongcheol Kim
      Jan 6, 2023

      Dyslipidemias, High Cholesterol, Hypercholesterolemia Trial in United States (Obicetrapib, Placebo)

      Recruiting
      • Dyslipidemias
      • +8 more
      • Sarasota, Florida
      • +11 more
      Aug 10, 2022

      Hypercholesterolemia, Hyperlipidemia Trial in Beijing (SHR-1209 ;)

      Active, not recruiting
      • Hypercholesterolemia
      • Hyperlipidemia
      • SHR-1209 ;placebo
      • Beijing, Beijing, China
        Beijing Anzhen Hospital, Capital Medical University
      May 23, 2022

      "My A:Care" and "Smart Coach" on Lipid-lowering Treatment

      Recruiting
      • Dyslipidemia
      • My A:care
      • Smart Coach
      • Khon Kaen, Thailand
        Chatlert Mueang Pongchaiyakul
      May 9, 2022

      Russian Coronary Heart Disease <<Treat to Goal>> (Study P05464)

      Completed
      Has Results
      • Coronary Heart Disease
      • Hypercholesterolemia
      • (no location specified)
      Feb 7, 2022

      Hypercholesterolemia Trial in Taipei (MK0733, simvastatin / Duration of Treatment: 12 Weeks)

      Completed
      • Hypercholesterolemia
      • MK0733, simvastatin / Duration of Treatment: 12 Weeks
      • Taipei, Taiwan
        Merck Sharp & Dohme (I.A.) Corp.
      Feb 7, 2022

      A 52-week Post-marketing, Observational Study to Confirm Safety

      Completed
      • Hypercholesterolemia
      • +2 more
      • Ezetimibe
      • Ezetimibe + other lipid-lowering medication(s)
      • (no location specified)
      Feb 7, 2022

      A 12-week Post-marketing, Observational Study to Confirm Safety

      Completed
      • Hypercholesterolemia
      • +2 more
      • Ezetimibe
      • Ezetimibe + other lipid-lowering medication(s)
      • (no location specified)
      Feb 7, 2022